Anton I. Rosenbaum

This study identifies 13 metabolites of the orally-bioavailable GLP-1 peptide MEDI7219 using in vitro pancreatin assays with CID and EAD fragmentation, revealing cleavage sites and enzyme-specific degradation patterns.

This study shows that MEDI5884 increases phosphatidylinositol levels in CAD patients by inhibiting endothelial lipase, correlating with improved HDL function and reverse cholesterol transport.